BSE Live
Apr 15, 10:23Prev. Close
53.08
Open Price
52.82
Bid Price (Qty.)
54.32 (25)
Offer Price (Qty.)
56.94 (17)
NSE Live
Dec 27, 11:22Prev. Close
-
Open Price
-
Bid Price (Qty.)
- (0)
Offer Price (Qty.)
- (0)
| Key Financial Ratios of OXYGENTA PHARMACEUTICAL (in Rs. Cr.) | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | -5.67 | -3.19 | -4.44 | -5.69 | -5.39 | |
| Diluted EPS (Rs.) | -5.67 | -3.19 | -4.44 | -5.69 | -5.39 | |
| Cash EPS (Rs.) | -4.69 | -2.19 | -3.52 | -4.81 | -4.58 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | -40.14 | -34.47 | -31.28 | -26.84 | -21.14 | |
| Book Value [InclRevalReserve]/Share (Rs.) | -40.14 | -34.47 | -31.28 | -26.84 | -21.14 | |
| Dividend / Share(Rs.) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Revenue from Operations/Share (Rs.) | 13.45 | 20.10 | 12.62 | 7.99 | 12.18 | |
| PBDIT/Share (Rs.) | -7.68 | -1.69 | -2.58 | -4.14 | -4.08 | |
| PBIT/Share (Rs.) | -8.66 | -2.69 | -3.51 | -5.02 | -4.89 | |
| PBT/Share (Rs.) | -5.82 | -3.42 | -4.39 | -5.61 | -5.39 | |
| Net Profit/Share (Rs.) | -5.67 | -3.19 | -4.44 | -5.69 | -5.39 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | -57.11 | -8.42 | -20.48 | -51.81 | -33.52 | |
| PBIT Margin (%) | -64.39 | -13.39 | -27.79 | -62.86 | -40.15 | |
| PBT Margin (%) | -43.31 | -17.03 | -34.80 | -70.19 | -44.26 | |
| Net Profit Margin (%) | -42.19 | -15.86 | -35.18 | -71.23 | -44.25 | |
| Return on Networth / Equity (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Return on Capital Employed (%) | -318.40 | -61.96 | 132.68 | -280.18 | 508.31 | |
| Return on Assets (%) | -31.08 | -15.37 | -26.69 | -30.46 | -27.82 | |
| Total Debt/Equity (X) | -0.63 | -0.61 | -0.56 | -0.68 | -0.77 | |
| Asset Turnover Ratio (%) | 73.66 | 96.92 | 75.86 | 42.76 | 62.86 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 0.43 | 0.53 | 0.22 | 0.34 | 0.26 | |
| Quick Ratio (X) | 0.16 | 0.21 | 0.14 | 0.23 | 0.22 | |
| Inventory Turnover Ratio (X) | 3.23 | 3.85 | 8.27 | 4.33 | 13.39 | |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Earnings Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cash Earnings Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 33.27 | 31.95 | 25.76 | 26.70 | 27.45 | |
| EV/Net Operating Revenue (X) | 2.43 | 1.56 | 2.00 | 3.27 | 2.21 | |
| EV/EBITDA (X) | -4.25 | -18.48 | -9.77 | -6.32 | -6.59 | |
| MarketCap/Net Operating Revenue (X) | 0.54 | 0.52 | 0.60 | 1.01 | 0.87 | |
| Retention Ratios (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Price/BV (X) | -0.18 | -0.30 | -0.24 | -0.30 | -0.50 | |
| Price/Net Operating Revenue | 0.54 | 0.52 | 0.60 | 1.01 | 0.87 | |
| Earnings Yield | -0.78 | -0.31 | -0.58 | -0.71 | -0.51 |
09.02.2026
OXYGENTA PHARMA Standalone December 2025 Net Sales at Rs 33.93 crore, up 2.18% Y-o-Y
12.11.2025
OXYGENTA PHARMA Standalone September 2025 Net Sales at Rs 14.30 crore, up 2.12% Y-o-Y
11.06.2025
OXYGENTA PHARMA Standalone March 2025 Net Sales at Rs 49.47 crore, up 368.77% Y-o-Y
25.11.2024
OXYGENTA PHARMA Standalone September 2024 Net Sales at Rs 14.01 crore, up 7.11% Y-o-Y
13.04.2026
13.04.2026
10.04.2026
09.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth